Table 3 Proportions of patients with adverse events during the study period
Adverse events (%) | Bumetanide plus placebo n = 16 | Bumetanide plus chlorthalidone n = 16 | p |
|---|---|---|---|
Impaired kidney function | 4 (25) | 11 (68.75) | 0.013 |
Creatinine doubling | 0 (0) | 0 (0) | - |
Hyponatremia | 1 (6) | 2 (12) | 1.000 |
Hypokalemia | 0 (0) | 2 (12) | 0.484 |
Hyperuricemia | 4 (25) | 4 (25) | 1.000 |
Cardiovascular events | 0 (0) | 1 (6) | 1.000 |
Mortality | 0 (0) | 0 (0) | - |